Key Points
-
Multipotent mesenchymal stromal cells (MSCs) are multipotent cells that were initially isolated from the bone marrow. They have been identified in almost all tissues and have a large number of immunomodulatory effects.
-
Based on their immunosuppressive activity, regenerative capacity and immunoprivileged status, MSCs are attractive tools for cellular therapy in inflammatory diseases and are currently being investigated in several clinical studies.
-
MSCs and the components of the innate immune system communicate at several levels, regulating for example the stem cell niche and antimicrobial responses.
-
MSCs residing in the bone marrow are strongly involved in the regulation of haematopoietic stem cell (HSC) homeostasis. Macrophages are an important partner in this process, as they positively regulate the expression of HSC-promoting factors by MSCs.
-
MSCs control the polarization of macrophages. Through the production of cyclooxygenase 2 and the expression of indoleamine 2,3-dioxygenase, MSCs induce interleukin-10-expressing anti-inflammatory M2 macrophages.
-
MSCs attract, activate and increase the lifespan of neutrophils. These beneficial effects can be enhanced by triggering innate immune sensors in MSCs and might support the clearance of pathogens.
-
Two types of MSC have been described, based on their pro-inflammatory (MSC1) and anti-inflammatory (MSC2) phenotypes. Microenvironmental stimuli — such as ligands for Toll-like receptor 3 (TLR3) and TLR4 — are fundamentally involved in this bidirectional polarization.
-
MSCs express several TLRs. Triggering them differentially can affect several biological functions, such as the differentiation, proliferation, migration, antioxidative repertoire and suppressive potency of MSCs.
-
The inflammatory pre-activation of MSCs, for example by interferon-γ, tumour necrosis factor or TLR ligands, is known as 'licensing' and enhances the suppressive activity of MSCs. Deciphering the underlying molecular mechanisms of this effect could help to improve the efficacy of MSC-based cell therapy.
Abstract
Multipotent mesenchymal stromal cells (MSCs) have unique immunoregulatory and regenerative properties that make them an attractive tool for the cellular treatment of autoimmunity and inflammation. Their underlying molecular mechanisms of action together with their clinical benefit — for example, in autoimmunity — are being revealed by an increasing number of clinical trials and preclinical studies of MSCs. However, autoimmunity and therapy-related alloimmunity are not only triggered and sustained by responses of the adaptive immune system; there is growing evidence that components of the innate immune system also have a key role. It is therefore important to study the crosstalk between MSCs and innate immunity, which ranges from the bone marrow niche to injured tissue.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Luria, E. A., Panasyuk, A. F. & Friedenstein, A. Y. Fibroblast colony formation from monolayer cultures of blood cells. Transfusion 11, 345–349 (1971).
Uccelli, A., Moretta, L. & Pistoia, V. Mesenchymal stem cells in health and disease. Nature Rev. Immunol. 8, 726–736 (2008).
Pittenger, M. F. et al. Multilineage potential of adult human mesenchymal stem cells. Science 284, 143–147 (1999).
Tremain, N. et al. MicroSAGE analysis of 2,353 expressed genes in a single cell-derived colony of undifferentiated human mesenchymal stem cells reveals mRNAs of multiple cell lineages. Stem Cells 19, 408–418 (2001).
Sacchetti, B. et al. Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell 131, 324–336 (2007).
Dominici, M. et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8, 315–317 (2006).
Le Blanc, K. et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 371, 1579–1586 (2008).
Duijvestein, M. et al. Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study. Gut 59, 1662–1669 (2010).
Ciccocioppo, R. et al. Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease. Gut 60, 788–798 (2011).
Connick, P. et al. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. Lancet Neurol. 11, 150–156 (2012).
Bachmann, M. F. & Kopf, M. On the role of the innate immunity in autoimmune disease. J. Exp. Med. 193, F47–F50 (2001).
Chow, A. et al. Bone marrow CD169+ macrophages promote the retention of hematopoietic stem and progenitor cells in the mesenchymal stem cell niche. J. Exp. Med. 208, 261–271 (2011). This paper shows for the first time how macrophages, in cooperation with nestin-expressing MSCs, regulate HSC mobilization.
Shi, C. et al. Bone marrow mesenchymal stem and progenitor cells induce monocyte emigration in response to circulating Toll-like receptor ligands. Immunity 34, 590–601 (2011). This study demonstrates that BM-MSCs sense systemic microbial challenges and, in response, can induce monocyte emigration.
Schofield, R. The stem cell system. Biomed. Pharmacother. 37, 375–380 (1983).
Wilson, A. & Trumpp, A. Bone-marrow haematopoietic-stem-cell niches. Nature Rev. Immunol. 6, 93–106 (2006).
Mendes, S. C., Robin, C. & Dzierzak, E. Mesenchymal progenitor cells localize within hematopoietic sites throughout ontogeny. Development 132, 1127–1136 (2005).
Friedenstein, A. J., Latzinik, N. W., Grosheva, A. G. & Gorskaya, U. F. Marrow microenvironment transfer by heterotopic transplantation of freshly isolated and cultured cells in porous sponges. Exp. Hematol. 10, 217–227 (1982).
Calvi, L. M. et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 425, 841–846 (2003).
Naveiras, O. et al. Bone-marrow adipocytes as negative regulators of the haematopoietic microenvironment. Nature 460, 259–263 (2009).
Mendez-Ferrer, S. et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 466, 829–834 (2010). This paper shows that nestin-expressing MSCs are crucial components of the bone marrow HSC niche and control HSC homeostasis.
Omatsu, Y. et al. The essential functions of adipo-osteogenic progenitors as the hematopoietic stem and progenitor cell niche. Immunity 33, 387–399 (2010). This study demonstrates the role of bone marrow-resident CAR cells in promoting both the self-renewal of HSCs and the maintenance of their undifferentiated state.
Sugiyama, T., Kohara, H., Noda, M. & Nagasawa, T. Maintenance of the hematopoietic stem cell pool by CXCL12–CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity 25, 977–988 (2006).
Mendez-Ferrer, S., Lucas, D., Battista, M. & Frenette, P. S. Haematopoietic stem cell release is regulated by circadian oscillations. Nature 452, 442–447 (2008).
Winkler, I. G. et al. Bone marrow macrophages maintain hematopoietic stem cell (HSC) niches and their depletion mobilizes HSCs. Blood 116, 4815–4828 (2010).
Liotta, F. et al. Toll-like receptors 3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing Notch signaling. Stem Cells 26, 279–289 (2008).
Bernardo, M. E., Cometa, A. M. & Locatelli, F. Mesenchymal stromal cells: a novel and effective strategy for facilitating engraftment and accelerating hematopoietic recovery after transplantation? Bone Marrow Transplant. 47, 323–329 (2011).
Koc, O. N. et al. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J. Clin. Oncol. 18, 307–316 (2000).
Cilloni, D. et al. Limited engraftment capacity of bone marrow-derived mesenchymal cells following T-cell-depleted hematopoietic stem cell transplantation. Blood 96, 3637–3643 (2000).
Rieger, K. et al. Mesenchymal stem cells remain of host origin even a long time after allogeneic peripheral blood stem cell or bone marrow transplantation. Exp. Hematol. 33, 605–611 (2005).
Phinney, D. G. & Prockop, D. J. Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair — current views. Stem Cells 25, 2896–2902 (2007).
Meirelles Lda, S., Fontes, A. M., Covas, D. T. & Caplan, A. I. Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine Growth Factor Rev. 20, 419–427 (2009).
Ganz, T. Epithelia: not just physical barriers. Proc. Natl Acad. Sci. USA 99, 3357–3358 (2002).
Signore, M. et al. Identity and ranking of colonic mesenchymal stromal cells. J. Cell. Physiol. 14 Dec 2011 (doi:10.1002/jcp.24027).
Diaz-Flores, L. et al. Pericytes. Morphofunction, interactions and pathology in a quiescent and activated mesenchymal cell niche. Histol. Histopathol. 24, 909–969 (2009).
Brittan, M. & Wright, N. A. Stem cell in gastrointestinal structure and neoplastic development. Gut 53, 899–910 (2004).
Brown, S. L. et al. Myd88-dependent positioning of Ptgs2-expressing stromal cells maintains colonic epithelial proliferation during injury. J. Clin. Invest. 117, 258–269 (2007).
Goessling, W. et al. Genetic interaction of PGE2 and Wnt signaling regulates developmental specification of stem cells and regeneration. Cell 136, 1136–1147 (2009).
Ferrand, J. et al. Human bone marrow-derived stem cells acquire epithelial characteristics through fusion with gastrointestinal epithelial cells. PLoS ONE 6, e19569 (2011).
Sasaki, M. et al. Mesenchymal stem cells are recruited into wounded skin and contribute to wound repair by transdifferentiation into multiple skin cell type. J. Immunol. 180, 2581–2587 (2008).
Prockop, D. J. “Stemness” does not explain the repair of many tissues by mesenchymal stem/multipotent stromal cells (MSCs). Clin. Pharmacol. Ther. 82, 241–243 (2007).
Lee, J. W., Fang, X., Gupta, N., Serikov, V. & Matthay, M. A. Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin-induced acute lung injury in the ex vivo perfused human lung. Proc. Natl Acad. Sci. USA 106, 16357–16362 (2009).
Semont, A. et al. Mesenchymal stem cells improve small intestinal integrity through regulation of endogenous epithelial cell homeostasis. Cell Death Differ. 17, 952–961 (2010).
Jakob, M. et al. Human nasal mucosa contains tissue-resident immunologically responsive mesenchymal stromal cells. Stem Cells Dev. 19, 635–644 (2010).
Lanzoni, G. et al. Isolation of stem cell populations with trophic and immunoregulatory functions from human intestinal tissues: potential for cell therapy in inflammatory bowel disease. Cytotherapy 11, 1020–1031 (2009).
Powell, D. W., Pinchuk, I. V., Saada, J. I., Chen, X. & Mifflin, R. C. Mesenchymal cells of the intestinal lamina propria. Annu. Rev. Physiol. 73, 213–237 (2011).
Chen, L., Tredget, E. E., Wu, P. Y. & Wu, Y. Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PLoS ONE 3, e1886 (2008).
Nemeth, K. et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E2-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nature Med. 15, 42–49 (2009). Here, the authors show how adoptive transfer of MSCs decreases lethality in a sepsis model by inducing regulatory IL-10+ macrophages (among other effects).
Mosser, D. M. & Edwards, J. P. Exploring the full spectrum of macrophage activation. Nature Rev. Immunol. 8, 958–969 (2008).
Maggini, J. et al. Mouse bone marrow-derived mesenchymal stromal cells turn activated macrophages into a regulatory-like profile. PLoS ONE 5, e9252 (2010).
Karp, J. M. & Leng Teo, G. S. Mesenchymal stem cell homing: the devil is in the details. Cell Stem Cell 4, 206–216 (2009).
Lee, R. H. et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 5, 54–63 (2009).
Kim, J. & Hematti, P. Mesenchymal stem cell-educated macrophages: a novel type of alternatively activated macrophages. Exp. Hematol. 37, 1445–1453 (2009).
Francois, M., Romieu-Mourez, R., Li, M. & Galipeau, J. Human MSC suppression correlates with cytokine induction of indoleamine 2,3-dioxygenase and bystander M2 macrophage differentiation. Mol. Ther. 20, 187–195 (2011).
Croitoru-Lamoury, J. et al. Interferon-γ regulates the proliferation and differentiation of mesenchymal stem cells via activation of indoleamine 2,3 dioxygenase (IDO). PLoS ONE 6, e14698 (2011).
Mougiakakos, D. et al. The impact of inflammatory licensing on heme oxygenase-1-mediated induction of regulatory T cells by human mesenchymal stem cells. Blood 117, 4826–4835 (2011).
Gupta, N. et al. Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice. J. Immunol. 179, 1855–1863 (2007).
Choi, H., Lee, R. H., Bazhanov, N., Oh, J. Y. & Prockop, D. J. Anti-inflammatory protein TSG-6 secreted by activated MSCs attenuates zymosan-induced mouse peritonitis by decreasing TLR2/NF-κB signaling in resident macrophages. Blood 118, 330–338 (2011). In this study, the authors show that MSCs secrete the multifunctional protein TSG6 and thereby suppress inflammatory responses by macrophages.
Ortiz, L. A. et al. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc. Natl Acad. Sci. USA 104, 11002–11007 (2007).
Groh, M. E., Maitra, B., Szekely, E. & Koc, O. N. Human mesenchymal stem cells require monocyte-mediated activation to suppress alloreactive T cells. Exp. Hematol. 33, 928–934 (2005).
Cassatella, M. A. et al. Toll-like receptor-3-activated human mesenchymal stromal cells significantly prolong the survival and function of neutrophils. Stem Cells 29, 1001–1011 (2011).
Raffaghello, L. et al. Human mesenchymal stem cells inhibit neutrophil apoptosis: a model for neutrophil preservation in the bone marrow niche. Stem Cells 26, 151–162 (2008). This study was the first to show that MSCs can have beneficial effects for neutrophils.
Tate, M. D. et al. Neutrophils ameliorate lung injury and the development of severe disease during influenza infection. J. Immunol. 183, 7441–7450 (2009).
Brandau, S. et al. Tissue-resident mesenchymal stem cells attract peripheral blood neutrophils and enhance their inflammatory activity in response to microbial challenge. J. Leukoc. Biol. 88, 1005–1015 (2010).
Romieu-Mourez, R. et al. Cytokine modulation of TLR expression and activation in mesenchymal stromal cells leads to a proinflammatory phenotype. J. Immunol. 182, 7963–7973 (2009).
Bischoff, S. C. Role of mast cells in allergic and non-allergic immune responses: comparison of human and murine data. Nature Rev. Immunol. 7, 93–104 (2007).
Brown, J. M., Nemeth, K., Kushnir-Sukhov, N. M., Metcalfe, D. D. & Mezey, E. Bone marrow stromal cells inhibit mast cell function via a COX2-dependent mechanism. Clin. Exp. Allergy 41, 526–534 (2011).
Su, W. R., Zhang, Q. Z., Shi, S. H., Nguyen, A. L. & Le, A. D. Human gingiva-derived mesenchymal stromal cells attenuate contact hypersensitivity via prostaglandin E2-dependent mechanisms. Stem Cells 29, 1849–1860 (2011).
Kavanagh, H. & Mahon, B. P. Allogeneic mesenchymal stem cells prevent allergic airway inflammation by inducing murine regulatory T cells. Allergy 66, 523–531 (2011).
Bouffi, C., Bony, C., Courties, G., Jorgensen, C. & Noel, D. IL-6-dependent PGE2 secretion by mesenchymal stem cells inhibits local inflammation in experimental arthritis. PLoS ONE 5, e14247 (2010).
Rasmusson, I., Ringden, O., Sundberg, B. & Le Blanc, K. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 76, 1208–1213 (2003).
Poggi, A. et al. Interaction between human NK cells and bone marrow stromal cells induces NK cell triggering: role of NKp30 and NKG2D receptors. J. Immunol. 175, 6352–6360 (2005).
Spaggiari, G. M., Capobianco, A., Becchetti, S., Mingari, M. C. & Moretta, L. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 107, 1484–1490 (2006). This paper showed how MSCs can inhibit NK cell function.
Patel, S. A. et al. Mesenchymal stem cells protect breast cancer cells through regulatory T cells: role of mesenchymal stem cell-derived TGF-β. J. Immunol. 184, 5885–5894 (2010).
Sotiropoulou, P. A., Perez, S. A., Gritzapis, A. D., Baxevanis, C. N. & Papamichail, M. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 24, 74–85 (2006).
Aggarwal, S. & Pittenger, M. F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105, 1815–1822 (2005).
Spaggiari, G. M. et al. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2, 3-dioxygenase and prostaglandin E2. Blood 111, 1327–1333 (2008).
Selmani, Z. et al. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells 26, 212–222 (2008).
Gotherstrom, C. et al. Fetal and adult multipotent mesenchymal stromal cells are killed by different pathways. Cytotherapy 13, 269–278 (2011).
Krampera, M. et al. Role for interferon-γ in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 24, 386–398 (2006).
Stockinger, B., Veldhoen, M. & Martin, B. Th17 T cells: linking innate and adaptive immunity. Semin. Immunol. 19, 353–361 (2007).
Geddes, K. et al. Identification of an innate T helper type 17 response to intestinal bacterial pathogens. Nature Med. 17, 837–844 (2011).
Korn, T., Bettelli, E., Oukka, M. & Kuchroo, V. K. IL-17 and Th17 Cells. Annu. Rev. Immunol. 27, 485–517 (2009).
Huang, W., La Russa, V., Alzoubi, A. & Schwarzenberger, P. Interleukin-17A: a T-cell-derived growth factor for murine and human mesenchymal stem cells. Stem Cells 24, 1512–1518 (2006). This study shows that IL-17A promotes the survival and proliferation of MSCs, thus forming a possible negative-feedback circuit.
Bai, L. et al. Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. Glia 57, 1192–1203 (2009).
Rafei, M. et al. Mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent manner. J. Immunol. 182, 5994–6002 (2009).
Ghannam, S., Pene, J., Torcy-Moquet, G., Jorgensen, C. & Yssel, H. Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. J. Immunol. 185, 302–312 (2010). This study demonstrates that MSCs favour the generation of FOXP3+ T Reg cells over that of T H 17 cells, and also shows that MSCs can reprogramme already differentiated pro-inflammatory T H 17 cells into suppressive T Reg cells.
Duffy, M. M. et al. Mesenchymal stem cell inhibition of T-helper 17 differentiation is triggered by cell–cell contact and mediated by prostaglandin E2 via the EP4 receptor. Eur. J. Immunol. 41, 2840–2851 (2011).
Tso, G. H., Law, H. K., Tu, W., Chan, G. C. & Lau, Y. L. Phagocytosis of apoptotic cells modulates mesenchymal stem cells osteogenic differentiation to enhance IL-17 and RANKL expression on CD4+ T cells. Stem Cells 28, 939–954 (2010).
Tatara, R. et al. Mesenchymal stromal cells inhibit Th17 but not regulatory T-cell differentiation. Cytotherapy 13, 686–694 (2011).
Carrion, F., Nova, E., Luz, P., Apablaza, F. & Figueroa, F. Opposing effect of mesenchymal stem cells on Th1 and Th17 cell polarization according to the state of CD4+ T cell activation. Immunol. Lett. 135, 10–16 (2011).
Darlington, P. J. et al. Reciprocal Th1 and Th17 regulation by mesenchymal stem cells: Implication for multiple sclerosis. Ann. Neurol. 68, 540–545 (2010).
Markiewski, M. M. & Lambris, J. D. The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am. J. Pathol. 171, 715–727 (2007).
Schraufstatter, I. U., Discipio, R. G., Zhao, M. & Khaldoyanidi, S. K. C3a and C5a are chemotactic factors for human mesenchymal stem cells, which cause prolonged ERK1/2 phosphorylation. J. Immunol. 182, 3827–3836 (2009). This was one of the first studies to establish a connection between the complement system and MSCs.
Mougiakakos, D., Johansson, C. C., Jitschin, R., Bottcher, M. & Kiessling, R. Increased thioredoxin-1 production in human naturally occurring regulatory T cells confers enhanced tolerance to oxidative stress. Blood 117, 857–861 (2011).
Schraufstatter, I. U., Discipio, R. G. & Khaldoyanidi, S. Mesenchymal stem cells and their microenvironment. Front. Biosci. 17, 2271–2288 (2011).
Toma, C., Wagner, W. R., Bowry, S., Schwartz, A. & Villanueva, F. Fate of culture-expanded mesenchymal stem cells in the microvasculature: in vivo observations of cell kinetics. Circ. Res. 104, 398–402 (2009).
Ratajczak, J. et al. Mobilization studies in mice deficient in either C3 or C3a receptor (C3aR) reveal a novel role for complement in retention of hematopoietic stem/progenitor cells in bone marrow. Blood 103, 2071–2078 (2004).
Moll, G. et al. Mesenchymal stromal cells engage complement and complement receptor bearing innate effector cells to modulate immune responses. PLoS ONE 6, e21703 (2011).
Komoda, H. et al. Reduction of N-glycolylneuraminic acid xenoantigen on human adipose tissue-derived stromal cells/mesenchymal stem cells leads to safer and more useful cell sources for various stem cell therapies. Tissue Eng. Part A 16, 1143–1155 (2010).
Ignatius, A. et al. Complement C3a and C5a modulate osteoclast formation and inflammatory response of osteoblasts in synergism with IL-1β. J. Cell. Biochem. 112, 2594–2605 (2011).
Tu, Z., Li, Q., Bu, H. & Lin, F. Mesenchymal stem cells inhibit complement activation by secreting factor H. Stem Cells Dev. 19, 1803–1809 (2010).
Nilsson, B., Ekdahl, K. N. & Korsgren, O. Control of instant blood-mediated inflammatory reaction to improve islets of Langerhans engraftment. Curr. Opin. Organ Transplant. 16, 620–626 (2011).
Kawai, T. & Akira, S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nature Immunol. 11, 373–384 (2010).
Lombardo, E. et al. Toll-like receptor-mediated signaling in human adipose-derived stem cells: implications for immunogenicity and immunosuppressive potential. Tissue Eng. Part A 15, 1579–1589 (2009).
Opitz, C. A. et al. Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by inducing indoleamine-2,3-dioxygenase-1 via interferon-β and protein kinase R. Stem Cells 27, 909–919 (2009).
Tomchuck, S. L. et al. Toll-like receptors on human mesenchymal stem cells drive their migration and immunomodulating responses. Stem Cells 26, 99–107 (2008).
Pevsner-Fischer, M. et al. Toll-like receptors and their ligands control mesenchymal stem cell functions. Blood 109, 1422–1432 (2007). This was one of the first broader studies of TLRs in MSCs. It investigated their expression and also their effect on several basic MSC functions.
Tomic, S. et al. Immunomodulatory properties of mesenchymal stem cells derived from dental pulp and dental follicle are susceptible to activation by Toll-like receptor agonists. Stem Cells Dev. 20, 695–708 (2011).
van den Berk, L. C. et al. Toll-like receptor triggering in cord blood mesenchymal stem cells. J. Cell. Mol. Med. 13, 3415–3426 (2009).
Hwa Cho, H., Bae, Y. C. & Jung, J. S. Role of Toll-like receptors on human adipose-derived stromal cells. Stem Cells 24, 2744–2752 (2006).
Raicevic, G. et al. Inflammation modifies the pattern and the function of Toll-like receptors expressed by human mesenchymal stromal cells. Hum. Immunol. 71, 235–244 (2010).
Mo, I. F. et al. Prolonged exposure to bacterial toxins downregulated expression of Toll-like receptors in mesenchymal stromal cell-derived osteoprogenitors. BMC Cell Biol. 9, 52 (2008).
Yu, S., Cho, H. H., Joo, H. J., Bae, Y. C. & Jung, J. S. Role of MyD88 in TLR agonist-induced functional alterations of human adipose tissue-derived mesenchymal stem cells. Mol. Cell. Biochem. 317, 143–150 (2008).
Sioud, M., Mobergslien, A., Boudabous, A. & Floisand, Y. Evidence for the involvement of galectin-3 in mesenchymal stem cell suppression of allogeneic T-cell proliferation. Scand. J. Immunol. 71, 267–274 (2010).
Kim, H. S. et al. Implication of NOD1 and NOD2 for the differentiation of multipotent mesenchymal stem cells derived from human umbilical cord blood. PLoS ONE 5, e15369 (2010). This study shows the presence of functional NOD-like receptors in MSCs.
Wang, Z. J. et al. Lipopolysaccharides can protect mesenchymal stem cells (MSCs) from oxidative stress-induced apoptosis and enhance proliferation of MSCs via Toll-like receptor(TLR)-4 and PI3K/Akt. Cell Biol. Int. 33, 665–674 (2009).
Nurmenniemi, S. et al. Toll-like receptor 9 ligands enhance mesenchymal stem cell invasion and expression of matrix metalloprotease-13. Exp. Cell Res. 316, 2676–2682 (2010).
DelaRosa, O. & Lombardo, E. Modulation of adult mesenchymal stem cells activity by Toll-like receptors: implications on therapeutic potential. Mediators Inflamm. 2010, 865601 (2010).
Marriott, I. Osteoblast responses to bacterial pathogens: a previously unappreciated role for bone-forming cells in host defense and disease progression. Immunol. Res. 30, 291–308 (2004).
Detante, O. et al. Intravenous administration of 99mTc-HMPAO-labeled human mesenchymal stem cells after stroke: in vivo imaging and biodistribution. Cell Transplant. 18, 1369–1379 (2009).
Waterman, R. S., Tomchuck, S. L., Henkle, S. L. & Betancourt, A. M. A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an immunosuppressive MSC2 phenotype. PLoS ONE 5, e10088 (2010). In this paper, the authors adapt the concept of M1 and M2 macrophages to MSC biology, and propose that differential triggering might result in either a pro-inflammatory MSC1 phenotype or an anti-inflammatory MSC2 phenotype.
Ferrari, D. et al. Purinergic stimulation of human mesenchymal stem cells potentiates their chemotactic response to CXCL12 and increases the homing capacity and production of proinflammatory cytokines. Exp. Hematol. 39, 360–374 (2011).
Gonzalez-Rey, E. et al. Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. Gut 58, 929–939 (2009).
Cavassani, K. A. et al. TLR3 is an endogenous sensor of tissue necrosis during acute inflammatory events. J. Exp. Med. 205, 2609–2621 (2008).
Ren, G. et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2, 141–150 (2008).
English, K., Barry, F. P., Field-Corbett, C. P. & Mahon, B. P. IFN-γ and TNF-α differentially regulate immunomodulation by murine mesenchymal stem cells. Immunol. Lett. 110, 91–100 (2007).
Polchert, D. et al. IFN-γ activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur. J. Immunol. 38, 1745–1755 (2008).
Chan, J. L. et al. Antigen-presenting property of mesenchymal stem cells occurs during a narrow window at low levels of interferon-γ. Blood 107, 4817–4824 (2006).
Abreu, M. T., Fukata, M. & Arditi, M. TLR signaling in the gut in health and disease. J. Immunol. 174, 4453–4460 (2005).
Taylor, P. A. et al. TLR agonists regulate alloresponses and uncover a critical role for donor APCs in allogeneic bone marrow rejection. Blood 112, 3508–3516 (2008).
Meisel, R. et al. Human but not murine multipotent mesenchymal stromal cells exhibit broad-spectrum antimicrobial effector function mediated by indoleamine 2,3-dioxygenase. Leukemia 25, 648–654 (2011). In this study, the authors demonstrate the polyfunctional nature of IDO in MSCs by showing that it has both immunomodulatory and antimicrobial effects.
Krasnodembskaya, A. et al. Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37. Stem Cells 28, 2229–2238 (2010).
Mei, S. H. et al. Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. Am. J. Respir. Crit. Care Med. 182, 1047–1057 (2010).
Karlsson, H. et al. Mesenchymal stem cells exert differential effects on alloantigen and virus-specific T-cell responses. Blood 112, 532–541 (2008).
Kang, H. S. et al. A paradoxical role for IFN-γ in the immune properties of mesenchymal stem cells during viral challenge. Exp. Hematol. 33, 796–803 (2005).
Smirnov, S. V. et al. Bone-marrow-derived mesenchymal stem cells as a target for cytomegalovirus infection: implications for hematopoiesis, self-renewal and differentiation potential. Virology 360, 6–16 (2007).
Sundin, M. et al. Persistence of human parvovirus B19 in multipotent mesenchymal stromal cells expressing the erythrocyte P antigen: implications for transplantation. Biol. Blood Marrow Transplant. 14, 1172–1179 (2008).
Morandi, F. et al. Immunogenicity of human mesenchymal stem cells in HLA-class I-restricted T-cell responses against viral or tumor-associated antigens. Stem Cells 26, 1275–1287 (2008).
Prigione, I. et al. Reciprocal interactions between human mesenchymal stem cells and γδ T cells or invariant natural killer T cells. Stem Cells 27, 693–702 (2009).
Nemeth, K. et al. Bone marrow stromal cells use TGF-β to suppress allergic responses in a mouse model of ragweed-induced asthma. Proc. Natl Acad. Sci. USA 107, 5652–5657 (2010).
Acknowledgements
The authors thank R. Jitschin for critically reviewing and discussing the manuscript. K.L.B. is supported by grants from the Cancer Society of Stockholm, the Children's Cancer Foundation, the Karolinska Institutet, Stockholm City Council, the Swedish Cancer Society, the Swedish Research Council, the Swedish Society of Medicine, the Tobias Foundation and VINNOVA. D.M. is supported by grants from the Interdisciplinary Center for Clinical Research at the University Hospital of the Erlangen and the German Research Foundation.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Related links
Glossary
- Mesenchymal
-
Embryonic tissues of mesodermal origin, consisting of loosely packed, unspecialized cells set in a gelatinous ground substance. Connective tissue, bone, cartilage and the circulatory and lymphatic systems all develop from mesenchymal cells.
- Colony-forming-unit fibroblasts
-
(CFU-fibroblasts). Freshly isolated single MSCs initiate colonies through clonal expansion. Their ability to form colonies still remains a key assay in the assessment of MSC function.
- Graft-versus-host disease
-
(GVHD). Following allogeneic bone marrow transplantation, donor-derived T cells can be activated by residual host-derived antigen-presenting cells. The resulting T cell reactivity can escalate into the life-threatening condition known as GVHD, which mainly targets the skin, liver and intestines.
- Crohn's disease
-
A chronic inflammatory disease of the gastrointestinal tract that is a type of inflammatory bowel disease. Autoimmune processes are thought to be involved in the pathogenesis of the disease.
- Multiple sclerosis
-
An inflammatory disease of the central nervous system. It leads to demyelination and axonal and neuronal degeneration, causing a broad range of neurological symptoms.
- Nestin
-
An intermediate filament that is usually found in neuronal (progenitor) cells. Its expression is associated with cell division, proliferation and morphological changes and might be characteristic of an immature type of MSC.
- Sympathetic nerve fibres
-
Part of the functional division of the autonomic nervous system that innervates the heart, lungs, gastrointestinal tract and sweat glands.
- Mesenchymal spheres
-
Cells with stem cell features (such as MSCs derived from diverse tissues) form spheres in vitro under non-adherent conditions.
- HSC-promoting factors
-
Growth factors, cytokines and other soluble or membrane-bound factors that determine the fate of haematopoietic stem cells (HSCs). They control key functions such as self-renewal, survival, quiescence, motility and adhesion. MSCs express several of these factors, including jagged 1, stem cell factor, CXCL12, angiopoietin 1, vascular cell adhesion molecule 1, intercellular adhesion molecule 1 and N-cadherin.
- Adrenergic signalling
-
Adrenergic nerves release the hormones and neurotransmitters adrenaline and noradrenaline. These molecules are agonists for the G-protein-coupled adrenergic receptors, activation of which leads to downstream alterations in second messengers (cyclic AMP or Ca2+) that widely promote an ergotropic state. Adrenergic receptors are found presynaptically and postsynaptically on the target organs and cells (including immune cells) of the sympathetic nervous system, which contributes to the regulation of vegetative functions.
- Haploidentical stem cell transplantation
-
Allogeneic stem cell transplantation with mismatches at all three histocompatibility loci (HLA-A, HLA-B and HLA-DRB1) is an alternative for patients without HLA-matched donors. However, crossing the major histocompatibility barrier can have substantial immunological consequences, namely graft-versus-host disease, graft rejection and delayed immune reconstitution.
- Wnt
-
A conserved family of paracrine signalling molecules. They regulate several developmental processes, such as proliferation and differentiation. Wnt signalling is, among other mechanisms, a key pathway for promoting epithelial cell proliferation in the intestine.
- Regulatory T cells
-
(TReg cells). A T cell subpopulation with T cell-suppressive capacities mediated by both cell–cell contact and soluble factors (such as TGFβ and IL-10). FOXP3 is the master transcription factor for TReg cells, and the population is essential for immunological homeostasis and the prevention of autoimmunity.
- M1 macrophages
-
Macrophages that have been activated by Toll-like receptor ligands (such as LPS) and interferon-γ and that express, among other molecules, inducible nitric oxide synthase and produce nitric oxide.
- M2 macrophages
-
Macrophages that have been stimulated by interleukin-4 (IL-4) or IL-13 and that express arginase 1, the mannose receptor CD206 and the IL-4 receptor α-chain.
- Indoleamine 2,3-dioxygenase
-
(IDO). An intracellular enzyme that catalyses the oxidative catabolism of L-tryptophan to N-formylkynurenine (KYN). Insufficient availability of the essential amino acid tryptophan and the presence of KYN promote immune tolerance by inducing T cell apoptosis and anergy and the generation of M2 macrophages (among other effects). Remarkably, tryptophan depletion also impedes microbial growth, thereby contributing to antimicrobial defence. MSCs express IDO.
- Cyclooxygenase 2
-
(COX2). An enzyme that initiates the conversion of arachidonic acid into prostaglandin E2 (PGE2). Its expression is inducible (in particular by inflammatory stimuli). MSCs produce and release PGE2, which is involved in several immunomodulatory effects, including the inhibition of dendritic cell maturation and the induction of IL-10+ macrophages.
- Zymosan
-
A polysaccharide isolated from yeast cell walls that is a ligand for Toll-like receptor 2. In macrophages, it elicits a pro-inflammatory response.
- TNF-stimulated gene 6
-
(TSG6). A multifunctional protein that is associated with inflammation and whose expression is upregulated in many cell types in response to various pro-inflammatory mediators. TSG6 has anti-inflammatory effects and could be part of a negative-feedback loop that downregulates inflammatory responses.
- Neutrophil extracellular traps
-
Webs of chromatin fibres that trap and kill microorganisms. Chromatin from the nuclei of neutrophils is extruded to form these extracellular nets, which also contain proteases from the azurophil granules of neutrophils.
- Respiratory burst
-
The process by which molecular oxygen is reduced by the NADPH oxidase system to produce reactive oxygen species. This process accompanies the exposure of neutrophils to microorganisms and/or pro-inflammatory mediators.
- Oxidative stress
-
Cells continuously produce reactive oxygen species (ROS) such as hydrogen peroxide or superoxide anions. Under physiological conditions, mitochondria are the main source, and cellular antioxidants ensure that the redox equilibrium is maintained. During inflammatory responses (and also in cancer), excessive production of ROS leads to a metabolic condition known as oxidative stress, which can lead to apoptosis and necrosis.
- Experimental autoimmune encephalomyelitis
-
(EAE). An experimental animal model of the human autoimmune disease multiple sclerosis. It is induced by immunization with myelin components such as myelin-oligodendrocyte glycoprotein (MOG) and myelin basic protein (MBP). Inflammation of the central nervous system leads to demyelination and paralysis.
- Complement system
-
Three independent pathways can initiate the complement cascade. The classical pathway is activated by antigen–antibody immune complexes. The alternative pathway is triggered by direct hydrolysis of complement component C3, and activation of the lectin pathway results from the binding of lectin to mannose residues on the surface of pathogens.
- Reactive oxygen species
-
(ROS). The metabolism of oxygen, and in particular its reduction through the mitochondrial electron-transport chain, generates by-products such as superoxide (O2), hydrogen peroxide (H2O2) and hydroxyl radicals (•OH). These three species and the unstable intermediates that are formed by lipid peroxidation are referred to as ROS. ROS can damage important intracellular targets such as DNA, carbohydrates and proteins.
- Carboxypeptidase N
-
An enzyme that regulates biologically active peptides (including the complement anaphylatoxin C3a) by removing carboxy-terminal arginine or lysine residues.
- Pattern-recognition receptors
-
(PRRs). PRRs detect microbial non-self molecules and endogenous danger signals and initiate immune responses. Several types of PRR, which reside either on the cell surface or in the cytoplasm, have been described. These include Toll-like receptors, scavenger receptors, mannose receptors and NOD-like receptors.
- Inflammatory MSC licensing
-
Pro-inflammatory mediators such as IFNγ and TNF activate ('license') MSCs to be immunosuppressive or to boost their suppressive potency. As these pro-inflammatory cytokines are mainly derived from immune effector cells such as T cells, which in turn are inhibited by MSCs, inflammatory licensing is thought to be part of a negative-feedback loop.
- Inflammasome
-
A cytosolic multiprotein complex that activates the inflammatory cascade. When triggered, it activates the protease caspase 1, which cleaves pro-IL-1β and pro-IL-18 into their active pro-inflammatory cytokine forms.
Rights and permissions
About this article
Cite this article
Le Blanc, K., Mougiakakos, D. Multipotent mesenchymal stromal cells and the innate immune system. Nat Rev Immunol 12, 383–396 (2012). https://doi.org/10.1038/nri3209
Published:
Issue Date:
DOI: https://doi.org/10.1038/nri3209
This article is cited by
-
Lipopolysaccharide alters VEGF-A secretion of mesenchymal stem cells via the integrin β3-PI3K-AKT pathway
Molecular & Cellular Toxicology (2024)
-
Mesenchymal stromal cell-associated migrasomes: a new source of chemoattractant for cells of hematopoietic origin
Cell Communication and Signaling (2023)
-
The effect of human menstrual blood-derived stem cells on ovarian folliculogenesis, angiogenesis and collagen volume in female rats affected by the polycystic ovary syndrome
Journal of Ovarian Research (2023)
-
Emerging role of mesenchymal stromal cells in gynecologic cancer therapy
Stem Cell Research & Therapy (2023)
-
Human osteoarthritic articular cartilage stem cells suppress osteoclasts and improve subchondral bone remodeling in experimental knee osteoarthritis partially by releasing TNFAIP3
Stem Cell Research & Therapy (2023)